Indian Journal of Pharmacology Home 

DRUG WATCH
[View FULLTEXT] [Download PDF]
Year : 2013  |  Volume : 45  |  Issue : 5  |  Page : 526--527

Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant

Darshak Makadia1, Sirisha Rani Siddaiahgari1, MS Latha2 
1 Department of Pediatrics and Pediatric Hemato Oncology, Rainbow Children's Tertiary Care Centre, Hyderabad, Andhra Pradesh, India
2 Department of Pharmacology, Hyderabad, Andhra Pradesh, India

Correspondence Address:
Sirisha Rani Siddaiahgari
Department of Pediatrics and Pediatric Hemato Oncology, Rainbow Children«SQ»s Tertiary Care Centre, Hyderabad, Andhra Pradesh
India

Autoimmune hemolytic anemia (AIHA) is an immune mediated destruction of erythrocytes, which has a good prognosis in children. It is known to have chronic, remitting or relapsing course, especially in infants and adolescents. Treatment of refractory or relapsing AIHA is a challenge as the other aim of the treatment is to avoid prolonged exposure to steroids or other immunosuppressants in small children. Rituximab is used in patients who are non-responsive to conventional treatment such as steroids, intravenous immunoglobulins and transfusion therapy. It has varying therapeutic success rate. We report a case of AIHA in a 4-month-old infant who had ill-sustained response to conventional therapy, but responded to rituximab.


How to cite this article:
Makadia D, Siddaiahgari SR, Latha M S. Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant.Indian J Pharmacol 2013;45:526-527


How to cite this URL:
Makadia D, Siddaiahgari SR, Latha M S. Anti B cell targeted therapy for autoimmune hemolytic anemia in an infant. Indian J Pharmacol [serial online] 2013 [cited 2019 Jul 20 ];45:526-527
Available from: http://www.ijp-online.com/article.asp?issn=0253-7613;year=2013;volume=45;issue=5;spage=526;epage=527;aulast=Makadia;type=0